ヘリコバクターピロリ（ピロリ菌）非侵襲的検査の世界市場規模：検査タイプ別、エンドユーザー別、地域別、範囲および予測

ヘリコバクターピロリ（ピロリ菌）非侵襲的検査の市場規模推移と予測

ヘリコバクターピロリ（ピロリ菌）非侵襲的検査市場規模は、2024年に6億9,030万米ドルと評価され、2026年から2032年にかけてCAGR 4.20%で成長し、2032年には9億3,082万米ドルに達すると予測されています。

ヘリコバクターピロリ（ピロリ菌）非侵襲的検査には、内視鏡検査を必要とせずにピロリ菌感染を診断する尿素呼気試験、便中抗原試験、血清学的検査が含まれます。尿素呼気検査では、ピロリ菌が代謝する炭素同位体で標識された尿素溶液を摂取し、呼気中の二酸化炭素を検出します。便中抗原検査は便中のピロリ菌タンパク質を検出し、血清検査は血流中のピロリ菌に対する抗体を検出します。

これらの検査は、消化性潰瘍や胃がんの主な原因であるピロリ菌感染を判定する上で非常に重要です。この検査は、内視鏡的生検などの侵襲的な治療に代わる、便利で患者に優しい治療法を提供します。非侵襲的検査は、ピロリ菌に関連した病気のリスクがある集団の初期診断、治療後のモニタリング、スクリーニングに不可欠です。

非侵襲的検査の進歩は、精度の向上、コストの削減、利用しやすさの向上を目的としています。分子技術やpoint-of-care診断などの新しい技術は、幅広いスクリーニングと早期介入を可能にするピロリ菌検出を変革します。個別化医療のアプローチには、ピロリ菌関連疾患の世界の負担を軽減する治療戦略を適応させるための非侵襲的診断も含まれる可能性があります。

ヘリコバクターピロリ（ピロリ菌）非侵襲的検査の世界市場力学

主な市場促進要因

ピロリ菌感染の有病率の増加：特に発展途上国におけるピロリ菌感染の世界の発生率の上昇が、非侵襲的検査の需要を促進しています。消化性潰瘍や胃がんなど、ピロリ菌に関連する健康被害が認識され、迅速でアクセスしやすい診断ツールの重要性が強調されています。

非侵襲的診断法の嗜好：尿素呼気試験、便中抗原検査、血清学的検査などの非侵襲的検査は、侵襲的治療と比較して、患者の快適性の向上、合併症のリスクの低下、投与の容易さなど、いくつかの利点を提供します。このような嗜好は、臨床現場における非侵襲的診断の使用を促進します。

技術の進歩と革新：より正確で費用対効果が高く、迅速な検査法の開発など、診断技術の絶え間ない開拓が市場拡大の原動力となっています。分子診断やポイント・オブ・ケア検査における技術革新は、ピロリ菌診断の効率性とアクセシビリティを向上させ、市場の成長を後押しします。

主な課題

正確性と信頼性への懸念ピロリ菌の非侵襲的診断法は便利ではあるが、時として偽陽性や偽陰性を示すことがあります。特に血清検査では、検査精度にばらつきがあり、現在の病気ではなく過去の病気が判明する可能性があるため、信頼性の高い診断やサーベイランスを行うことが困難です。

コストと利用しやすさの問題：技術開発にもかかわらず、尿素呼気試験のような特定の非侵襲的診断法のコストは、特に低所得者層で広く使用するには高すぎる場合があります。農村部や十分なサービスを受けていない地域では、高度な検査施設や設備へのアクセスが限られているため、こうした診断アプローチの普及が妨げられています。

抗生物質耐性：抗生物質耐性の増加はピロリ菌感染の治療に影響を及ぼします。適切な治療を行うためには、非侵襲的検査に加え、抗生物質感受性検査を実施する必要があるが、この検査は複雑であり、診断にかかる費用と期間を増大させる可能性があります。

主な動向：

ポイントオブケア検査の採用：市場は、患者のいる場所で迅速かつ正確な結果を提供するポイントオブケア（POC）診断機器へとシフトしています。このようなポイントオブケア診断機器は、アクセシビリティを向上させ、待ち時間を最小限に抑え、患者のコンプライアンスを向上させるため、プライマリケアの現場や遠隔地で特に有用です。

高度な分子診断の統合：非侵襲的ピロリ菌検査では、ポリメラーゼ連鎖反応（PCR）や次世代シークエンシング（NGS）などの分子診断技術の使用が増加しています。これらのアプローチは感度と特異性を向上させ、より正確な感染の検出と特徴付けを可能にしています。

個別化医療と標的療法：個別化医療の拡大傾向はピロリ菌検査市場に影響を与えています。細菌の存在を検出すると同時に、抗生物質耐性パターンに関する情報を提供する非侵襲的アッセイが開発されています。この情報により、患者一人ひとりの疾患プロファイルに合わせた治療戦略が可能になり、治療成績が向上し、抗生物質耐性のリスクが低下します。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 ヘリコバクターピロリ（ピロリ菌）非侵襲的検査市場：検査タイプ別（診断）

• 尿素呼気試験（UBT）
• 便中抗原検査（HpSA）
• 血清学的検査

第5章 ヘリコバクターピロリ（ピロリ菌）非侵襲的検査市場：エンドユーザー別

• 病院
• 診断ラボ
• 診療所

第6章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第7章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第8章 競合情勢

• 主要企業
• 市場シェア分析

第9章 企業プロファイル

• Abbott
• Biomerica, Inc.
• Certest Biotec S.L.
• CorisBioconcept SPRL
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• Meridian Bioscience, Inc.
• Sekisui Diagnostics
• Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.

第10章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第11章 市場展望付録

• 略語リスト
• 出典と参考文献

Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Size And Forecast

Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market size was valued at USD 690.3 Million in 2024 and is projected to reach USD 930.82 Million by 2032, growing at a CAGR of 4.20% from 2026 to 2032.

Helicobacter pylori (H. pylori) non-invasive testing includes urea breath tests, stool antigen tests and serology tests that diagnose H. pylori infection without the need for an endoscopy. The urea breath test involves consuming a urea solution labeled with a carbon isotope which H. pylori metabolizes resulting in detectable carbon dioxide in the breath. Stool antigen tests detect H. pylori proteins in feces whereas serology tests detect antibodies to H. pylori in the bloodstream.

These tests are critical in determining H. pylori infection which is a leading cause of peptic ulcers and stomach cancer. They provide a convenient and patient-friendly alternative to invasive treatments such as endoscopic biopsies. Non-invasive testing is critical for initial diagnosis, post-treatment monitoring and screening in populations at risk of H. pylori-related illnesses.

Non-invasive testing advancements are intended to improve accuracy, lower costs and increase accessibility. Emerging technologies such as molecular techniques and point-of-care diagnostics are set to transform H. pylori detection allowing for broad screening and early intervention. Personalized medicine approaches may also include non-invasive diagnostics to adapt treatment strategies lowering the worldwide burden of H. pylori-related disorders.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Dynamics

The key market dynamics that are shaping the global helicobacter pylori (h. pylori) non-invasive testing market include:

Key Market Drivers:

Increased Prevalence of H. Pylori Infections: The rising global incidence of H. pylori infections particularly in developing nations is driving the demand for non-invasive testing. Recognizing the health hazards associated with H. pylori such as peptic ulcers and stomach cancer emphasizes the importance of quick and accessible diagnostic tools.

Preference for Non-Invasive Diagnostic Methods: Non-invasive examinations such as urea breath tests, stool antigen testing and serology tests provide several advantages over invasive treatments including increased patient comfort, a lower risk of complications and ease of administration. This preference promotes the use of non-invasive diagnostics in clinical settings.

Technological Advancements and Innovation: Constant developments in diagnostic technology such as the creation of more accurate, cost-effective and rapid testing methods drive market expansion. Innovations in molecular diagnostics and point-of-care testing improve the efficiency and accessibility of H. pylori diagnosis propelling market growth.

Key Challenges:

Accuracy and Reliability Concerns: Non-invasive diagnostics for H. pylori while handy, can occasionally provide false positives or negatives. Variations in test accuracy particularly with serology tests that may reveal past rather than current illnesses make it difficult to provide reliable diagnosis and surveillance.

Cost and Accessibility Issues: Despite technical developments, the cost of certain non-invasive diagnostics such as the urea breath test can be too expensive for broad use especially in low-income communities. Limited access to advanced testing facilities and equipment in rural and underserved areas impedes widespread use of these diagnostic approaches.

Antibiotic Resistance: The increasing prevalence of antibiotic resistance affects the treatment of H. pylori infections. Non-invasive tests must be supplemented by antibiotic susceptibility testing to ensure appropriate therapy which adds complexity and may increase the cost and duration of the diagnostic procedure.

Key Trends:

Adoption of Point-of-Care Testing: The market is shifting toward point-of-care (POC) diagnostic instruments that deliver quick and precise results at the patient's location. These point-of-care diagnostics improve accessibility, minimize wait times and increase patient compliance making them especially useful in primary care settings and remote places.

Integration of Advanced Molecular Diagnostics: In non-invasive H. pylori testing, molecular diagnostic technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are increasingly being used. These approaches have improved sensitivity and specificity allowing for more precise detection and characterization of infections.

Personalized Medicine and Targeted Therapy: The expanding trend of personalized medicine is influencing the H. pylori testing market. Non-invasive assays are being developed to detect the presence of bacteria while simultaneously providing information about antibiotic resistance patterns. This information allows treatment strategies to be tailored to each individual patient's illness profile increasing treatment outcomes and lowering the risk of antibiotic resistance.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Regional Analysis

Here is a more detailed regional analysis of the global Helicobacter pylori (H. pylori) non-invasive testing market:

North America:

According to Verified Market Research analyst, North America is expected to dominate the global Helicobacter pylori (H. pylori) non-invasive testing market.

The region's dominance is due to a number of major factors. The region's high healthcare expenditure ensures access to new diagnostic technologies and allows for the rapid adoption of innovative, non-invasive testing methods. Furthermore, favorable payment rules significantly reduce patient's out-of-pocket expenses making these tests more affordable and encouraging widespread adoption. The combination of robust healthcare infrastructure and strong financial incentives fosters market expansion.

Furthermore, North America has a large patient population with H. pylori infections which fuels demand for diagnostic testing. Awareness campaigns and public health initiatives also play an important role in promoting early detection and regular screening which helps grow the market. The region's emphasis on preventative healthcare combined with the high frequency of gastrointestinal illnesses associated with H. pylori highlights the vital need for dependable diagnostic solutions solidifying North America's dominance in the H. pylori non-invasive market.

Asia Pacific:

The Asia Pacific region is expected to become the fastest-growing market for H. pylori non-invasive testing market driven by rising infection rates. H. pylori infection rates are high in countries such as China, India and Japan necessitating appropriate diagnostic techniques to control and treat gastrointestinal problems. The increased incidence of H. pylori infections underscores the critical need for accessible and reliable diagnostic technologies which is driving market expansion in the region.

Growing healthcare infrastructure in Asia Pacific contributes greatly to this expansion. Investments in updating healthcare facilities and increasing access to innovative medical technologies are helping the region's diagnostic capacities. Governments and corporate entities are prioritizing healthcare advancements resulting in better-equipped hospitals and clinics which encourages the use of non-invasive H. pylori testing procedures.

The region's enormous population base creates a significant market opportunity for H. pylori non-invasive diagnostics. With Asia Pacific home to a sizable fraction of the world's population, there is an enormous potential need for diagnostic services. Furthermore, rising awareness of H. pylori-related health conditions as well as a growing middle class with better access to healthcare facilities are driving up demand for improved therapies. These factors combine to position the Asia Pacific region as a prominent player in the future growth of the H. pylori non-invasive testing market.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market: Segmentation Analysis

The Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market is segmented on the basis of Test Type, End User, and Geography.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Test Type

• Urea Breath Test (UBT)
• Stool Antigen Test (HpSA)
• Serological Testing

Based on Test Type, the market is Urea Breath Test (UBT), Stool Antigen Test (HpSA) and Serological Testing. The Urea Breath Test (UBT) dominates the H. pylori non-invasive testing market due to its high accuracy, non-invasiveness and rapid findings. UBT is preferred because it can detect active infections more accurately and is less impacted by recent antibiotic or proton pump inhibitor usage than other tests. It is the most reliable and patient-friendly method for diagnosing H. pylori infections.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By End User

• Hospitals
• Diagnostic Labs
• Clinics

Based on End User, the market is divided into Hospitals, Diagnostic Labs and Clinics. Hospitals dominate the market for H. pylori non-invasive testing because of their modern diagnostic centers, extensive patient care and high patient volume. Hospitals are frequently the primary facilities for diagnosing and treating gastrointestinal illnesses including H. pylori infections. Their comprehensive diagnostic test suite along with integrated care and follow-up therapies guarantees that they will always be the go-to option for precise and effective H. pylori testing.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market is classified into North America, Europe, Asia Pacific and the Rest of the world. North America dominates the H. pylori non-invasive testing market owing to high healthcare spending, attractive reimbursement rules and a large patient population. In contrast, the Asia Pacific region is rapidly emerging as the fastest-growing market driven by rising infection rates, improved healthcare infrastructure and a large population base that requires advanced diagnostic solutions.

Key Players

• The Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott, Biomerica Inc., Certest Biotec S.L., CorisBioconcept SPRL, DiaSorin S.p.A., Meridian Bioscience Inc., Sekisui Diagnostics and Shenzhen Zhonghe Headway Bio-Sci & Tech Co. Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

• Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Recent Developments
• In March 2023, RedHill, a speciality biopharmaceutical company declared that it has settled all of its debt, including principal, interest, revenue interest, prepayment premiums and exit costs. This contains RedHill Biopharma Inc.'s (the company's U.S. subsidiary) Credit Agreement with HCR.
• In July 2023, Meridian Bioscience received FDA clearance for Premier HpSA Flex, a significant advancement in non-invasive H. pylori diagnostic testing solutions. This milestone strengthened the company's position in the non-invasive H. pylori testing market.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market, By Test Type (Diagnostics)

• Urea Breath Test (UBT)
• Stool Antigen Test (HpSA)
• Serological Testing

5. Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market, By End User

• Hospitals
• Diagnostic Labs
• Clinics

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Abbott
• Biomerica, Inc.
• Certest Biotec S.L.
• CorisBioconcept SPRL
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• Meridian Bioscience, Inc.
• Sekisui Diagnostics
• Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References